论文部分内容阅读
目的观察唑来膦酸联合特立帕肽治疗绝经后骨质疏松症对骨密度(BMD)的影响。方法 60例绝经后骨质疏松症患者随机分成唑来膦酸组、特立帕肽组和特立帕肽+唑来膦酸组,观察各组用药后13、26和52周时腰椎、髋部和股骨颈BMD相对于基线的变化。结果特立帕肽+唑来膦酸组用药后13和26周的腰椎BMD增长百分比与唑来膦酸组、特立帕肽组相比存在显著差异(P<0.01)。用药后52周,特立帕肽+唑来膦酸组与特立帕肽组腰椎BMD无统计学差异,但显著高于唑来膦酸组(P<0.01)。唑来膦酸组、特立帕肽+唑来膦酸组用药后13、26和52周的髋部和股骨颈BMD增长百分比与特立帕肽组相比,差异有统计学意义(P<0.05),特立帕肽+唑来膦酸组用药后13周的髋部BMD增长百分比与唑来膦酸组相比,差异有统计学意义(P<0.05)。结论唑来膦酸和特立帕肽联合治疗对提高绝经后骨质疏松症患者的BMD有益。
Objective To observe the effect of zoledronic acid combined with teriparatide on bone mineral density (BMD) in postmenopausal osteoporosis. Methods Sixty patients with postmenopausal osteoporosis were randomly divided into zoledronic acid group, teriparatide group and teriparatide + zoledronic acid group. The levels of lumbar vertebra and hip were observed at 13, 26 and 52 weeks after treatment Department and femoral neck BMD relative to baseline changes. Results The percentages of lumbar spine BMD increase at 13 and 26 weeks after treatment with teriparatide and zoledronic acid were significantly different from those in zoledronic acid and teriparatide groups (P <0.01). At 52 weeks after treatment, there was no significant difference in BMD of lumbar vertebra between teriparatide + zoledronic acid group and teriparatide group, but significantly higher than that of zoledronic acid group (P <0.01). The percentages of increase of BMD in hip and femoral neck at 13, 26 and 52 weeks after taking zoledronic acid, teriparatide and zoledronic acid were statistically different from those in teriparatide group (P < 0.05). The percentage increase in hip BMD at 13 weeks after treatment with teriparatide and zoledronic acid was statistically different from that of zoledronic acid (P <0.05). Conclusion Combination of zoledronic acid and teriparatide is beneficial for improving BMD in postmenopausal osteoporosis patients.